27 Nov 2017 11:33
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 October 2017
Net Assets | £231m |
Net Assets per share | 616p |
Share price | 600p |
Total value of unquoted investments | £21m |
Total number of portfolio companies | 90 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Biogen | 7.3 |
Celgene | 5.9 |
Regeneron | 5.4 |
Vertex | 4.2 |
Exelixis | 3.6 |
Adamas | 3.5 |
Incyte | 3.3 |
Gilead | 3.0 |
Alexion | 3.0 |
Acadia | 2.7 |
----------- | |
Total | 41.9 |
Geographical Allocation | % NAV |
US & Canada | 89 |
Europe & UK | 11 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 91 |
Unquoted | 9 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 41 |
Mid Cap =USD1-10BN | 27 |
Small Cap | 32 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 35 |
Rare diseases | 13 |
CNS | 12 |
Inflammation | 9 |
Ophthalmology | 8 |
Infectious Diseases | 6 |
Metabolic | 6 |
Medtech | 2 |
Other | 9 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
27 NOVEMBER 2017